SPOTLIGHT: New CEO at Bridge
There's a new slate of executives running Bridge Pharmaceuticals, which has been touting its facilities in China for preclinical contract research services. D. Thomas Oakley, a Covance vet, is the new CEO, Patrik Jeanmonod has been promoted to CFO and Dr. Ronald J. Ma is the new chief scientific officer. No word on the fate of their predecessors, the CEO abruptly left the scene months ago, or what triggered the change up. Release
Be the first to comment
Comments
Post new comment
Paid Research Reports
- RNA therapy: the next big thing after monoclonal antibodies?
- Biotech M&A Strategies: Deal assessments, trends and future prospects
- The Dermatology Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities
- Pipeline Insight: Cancer Overview - Breast, Gynecological, Genitourinary - Diverse drugs approaching the market for many tumor t
- Sales Force Effectiveness
- Forecast Model: Antidyslipidemics - Genericization and negative trial data drive market shrinkage
